Innovation Validation Call 2027
Innovation Validation Call 2027 supports companies and their partners with clinical validation and market preparation for digital and AI-enabled medical devices to advance towards commercialisation.
Funder: European Commission
Due Dates: January 13, 2027 (Application deadline) | December 1, 2026, 15:00 CET (Open Q&A)
Funding Amounts: Up to €850,000 per project, covering up to 50% of the total budget; €5,100,000 available overall
Summary: EIT Health supports clinical validation and market preparation for digital and AI-enabled medical devices approaching commercialisation.
Key Information: A commercialising company must lead a consortium of at least two organisations from different countries.
Description
EIT Health’s Innovation Validation Call 2027 supports digital and AI-powered medical technologies ready for real-world clinical validation and approaching market launch. It addresses the funding gap for solutions needing clinical studies and evidence of safety and efficacy before regulatory approval and commercialisation. Supported activities include pivotal clinical studies, regulatory submission such as CE-mark application dossiers, product finalisation, market readiness, and commercial strategy.
The call is delivered through the European Commission-funded EIT Health Business Plan 2026–2028. It provides cascade funding: EIT Health runs the call and awards and pays the funding. Projects should advance eligible medical devices from Innovation Maturity Level (IML) 6 to IML 7, with the potential to reach EU patients and citizens and generate revenue after the funding period.
